Intervacc EBITDA

What does Intervacc do? Intervacc AB is a Swedish biotechnology company specializing in the development and production of vaccines for animals. The company was founded in 2003 by researchers who wanted to develop an alternative to traditional vaccines made from weakened or killed pathogens. Intervacc AB's business model is based on the development of subunit vaccines, which consist of the key proteins of the pathogens and allow targeted immune responses in animals. Subunit vaccines are safe and effective, offering many advantages over traditional vaccines by minimizing the risk of side effects and allowing targeted combat against specific pathogens. The different divisions at Intervacc AB include the development of vaccines for animals such as horses, pigs, chickens, and cattle. The company also has plans to develop vaccines for other animal species in the future, such as dogs and cats. Among the products offered by Intervacc AB are various vaccines in different stages of development. One of its key products is Equilis StrepE, used for the preventive treatment of myopathy in horses. The vaccination is already being used in many countries and is an important part of horse healthcare. Another product is Porcilis AR-T DF, used to vaccinate pigs against atrophic rhinitis (AR). Intervacc AB is also developing new products, such as a vaccine for the prevention of Lyme borreliosis in horses and a vaccine against bacterial pneumonia in calves. The company is constantly searching for new vaccines to improve animal health and welfare, and several patents have been filed. The history of Intervacc AB is marked by ambitious goals and scientific breakthroughs. In 2004, the first steps were taken towards developing subunit vaccines for horse diseases. In 2007, the company began clinical trials of Equilis StrepE, which was later acquired by Boehringer Ingelheim Animal Health in 2016. In 2011, Intervacc AB developed Porcilis AR-T DF, a vaccine against atrophic rhinitis in pigs. Since then, the company has expanded its research and development into various areas and formed numerous partnerships. Intervacc AB utilizes cutting-edge technologies and has an experienced team of scientists and professionals who collaborate closely to develop and test new vaccines. The company is based in Uppsala, Sweden, and has state-of-the-art laboratory and production facilities. Overall, Intervacc AB has established itself as an innovative company specializing in the development of safe and effective vaccines for animals. Its products and services contribute to improving the health and well-being of animals and making animal husbandry more sustainable and efficient. Intervacc is one of the most popular companies on Eulerpool.